Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T23499 | ||||
Target Name | Endothelin A receptor (EDNRA) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Ambrisentan | Drug Info | IC50 = 21.7 nM | ||
Bosentan | Drug Info | IC50 = 4.1~4.7 nM | [8] | ||
Sitaxsentan | Drug Info | IC50 = 1.4 nM | [7] | ||
Zibotentan | Drug Info | EC50 = 23 nM | [6] | ||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | Ki < 1000 nM | [5] | ||
Ac-bhg-F-N-Y-Y-W | Drug Info | IC50 = 1900 nM | |||
Asterric acid | Drug Info | IC50 = 10000 nM | [2] | ||
Bhg-F-N-Y-Y-W | Drug Info | IC50 = 9500 nM | |||
BMS-182874 | Drug Info | Ki = 55 nM | [1] | ||
BMS-193884 | Drug Info | Ki = 1.4 nM | [1] | ||
Endothelin-2 | Drug Info | IC50 = 0.288 nM | [4] | ||
PD-155080 | Drug Info | IC50 = 7.4 nM | |||
PD-163140 | Drug Info | IC50 = 0.35 nM | |||
Sparsentan | Drug Info | Ki = 1.9 nM | [3] | ||
Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys) | Drug Info | IC50 = 2800 nM | |||
Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys) | Drug Info | IC50 = 6500 nM | |||
W-F-F-N--Y-Y-W | Drug Info | IC50 = 2400 nM | |||
References | |||||
REF 1 | Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET... J Med Chem. 2000 Aug 10;43(16):3111-7. | ||||
REF 2 | New chlorinated diphenyl ethers from an Aspergillus species. J Nat Prod. 2002 Jan;65(1):7-10. | ||||
REF 3 | Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. | ||||
REF 4 | 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6. | ||||
REF 5 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | ||||
REF 6 | Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006;6(4):361-76. | ||||
REF 7 | The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house Br J Pharmacol. 2008 Mar;153(6):1105-19. | ||||
REF 8 | BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008 Dec;7(12):989-1000. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.